Scancell Holdings plc (LON:SCLP - Get Free Report)'s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 13.56 ($0.17) and traded as low as GBX 8.78 ($0.11). Scancell shares last traded at GBX 8.83 ($0.11), with a volume of 316,892 shares changing hands.
Scancell Stock Performance
The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of 61.41. The company has a market cap of £83.94 million, a price-to-earnings ratio of -903.00 and a beta of 0.35. The stock has a 50 day simple moving average of GBX 10.48 and a 200 day simple moving average of GBX 13.56.
Scancell (LON:SCLP - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share for the quarter. As a group, analysts predict that Scancell Holdings plc will post -2.5361112 EPS for the current year.
About Scancell
(
Get Free Report)
Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.
Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Scancell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.
While Scancell currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
